UP

UCB Pharma

Belgium - Brussels

Pharmaceutical

Website LinkedIn Careers Page

Focus: Small Molecules, Biologics

UCB Pharma is a life sciences company focused on Small Molecules, Biologics.

NeurologyImmunologyOncologyDermatologyRespiratory

Open Jobs

0

Products & Portfolio (18)

31 discontinued products not shown

mAbINJECTION · INJECTABLE

Bimekizumab-bkzx is a humanized immunoglobulin IgG1/ κ monoclonal antibody with two identical antigen binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex. IL-17A and IL-17F are naturally occurring cytokines that are involved in normal inflammatory and immune responses. Bimekizumab-bkzx inhibits the release of proinflammatory cytokines and chemokines.

moderate to severe plaque psoriasis in adultsphototherapypsoriasis

INTRAVENOUS · SOLUTION

Epoxide Hydrolase Inhibitors

partial-onset seizures in patients 1 month of ageolder

ORAL · SOLUTION

Epoxide Hydrolase Inhibitors

partial-onset seizures in patients 1 month of ageolder

Epoxide Hydrolase Inhibitors

partial-onset seizures in patients 1 month of ageolder

certolizumab pegol

LOE Approaching

mAbINJECTION · INJECTABLE

Tumor Necrosis Factor Receptor Blocking Activity

active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of ageolderCrohn's disease+2 more

ORAL · SOLUTION

Lennox-Gastaut syndrome is unknown. Fenfluramine and the metabolite, norfenfluramine, exhibit agonist activity at serotonin 5-HT2 receptors. There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine and norfenfluramine, and valvular heart disease and pulmonary arterial hypertension.

seizures associated with Dravet syndromeLennox-Gastaut syndrome in patients 2 years of ageolder

LOE Approaching

ORAL · SOLUTION

mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.

partial-onset seizures in patients 1 month of ageolderepilepsy

LOE Approaching

INTRAVENOUS · INJECTABLE

mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.

partial-onset seizures in patients 1 month of ageolderepilepsy

mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.

partial-onset seizures in patients 1 month of ageolderepilepsy

LOE Approaching

ORAL · TABLET, EXTENDED RELEASE

mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.

partial-onset seizures in patients 12 years of ageolder ( )

doxecitine and doxribtimine

ORAL · FOR SOLUTION

nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.

thymidine kinase 2 deficiency (TK2d) in adultsbefore 12 years

LOE Approaching

understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

View all 18 products

Pipeline & Clinical Trials

Lacosamide

Epilepsies, Partial

N/A

Clinical Trials (1)

NCT00771927Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

N/A

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process

N/A

Clinical Trials (1)

NCT00522522Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

N/A

Consulting with PARKINSUN as communication aid-tool

Parkinson's Disease

N/A

Clinical Trials (1)

NCT04179695Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care

N/A

Piracetam

Memory Disorders

N/A

Clinical Trials (1)

NCT00567060Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

N/A

Certolizumab Pegol

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT03559686Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

N/A

Levetiracetam

Premenstrual Dysphoric Disorder

N/A

Clinical Trials (1)

NCT00518570Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

N/A

Cimzia

Crohn's Disease

N/A

Clinical Trials (1)

NCT00844285SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

N/A

Rozanolixizumab

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

N/A

Clinical Trials (1)

NCT05014724CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

N/A

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Hidradenitis Suppurativa

N/A

Clinical Trials (1)

NCT04115566Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

N/A

Lacosamide

Healthy Male Volunteers

N/A

Clinical Trials (1)

NCT01382017Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study

N/A

certolizumab pegol

Crohn's Disease

N/A

Clinical Trials (1)

NCT01053559Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

N/A

Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis

Arthritis,Rheumatoid

N/A

Clinical Trials (1)

NCT01288287Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients

N/A

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

Refractory Epilepsy

N/A

Clinical Trials (1)

NCT04398667European Non-interventional Study on Refractory Epilepsy With Developmental Delay

N/A

Transdermal Rotigotine User Surveillance Study

Idiopathic Parkinson Disease

N/A

Clinical Trials (1)

NCT00599339Transdermal Rotigotine User Surveillance Study

N/A

A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis i

Axial Spondyloarthritis

N/A

Clinical Trials (1)

NCT02354105A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life

N/A

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01764321Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

N/A

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With

Idiopathic Parkinson's Disease

N/A

Clinical Trials (1)

NCT02227355Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease

N/A

Lercanidipine

N/A

Clinical Trials (1)

NCT00160498Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients

N/A

Brigham and Women's Rheumatoid Arthritis Sequential Study

Rheumatoid Arthritis

N/A

levetiracetam

N/A

Clinical Trials (1)

NCT00203216A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

N/A

Verily Study Watch

Progressive Supranuclear Palsy

N/A

Clinical Trials (1)

NCT05501431Personalized Parkinson Project PSP Cohort

N/A

Detecting Fatigue From Voice in Generalised Myasthenia Gravis

Myasthenia Gravis Generalised

N/A

Clinical Trials (1)

NCT07033559Detecting Fatigue From Voice in Generalised Myasthenia Gravis

N/A

cognitive rehabilitation

Cognitive Change

N/A

Clinical Trials (1)

NCT05057156Digital Solution to Improve Cognitive Function in Epilepsy: PRODDIGE Project

N/A

Brivaracetam

N/A

Clinical Trials (1)

NCT03532516Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

N/A

Usual Care

N/A

Clinical Trials (1)

NCT02646631Behavioral and Educational Tools to Improve Epilepsy Care

N/A

Lacosamide

Epilepsies, Partial

N/A

Clinical Trials (1)

NCT03559673Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures

N/A

Levetiracetam

N/A

Clinical Trials (1)

NCT00254657Levetiracetam for Treatment of Pain Associated With Fibromyalgia

N/A

Musculoskeletal Ultrasound Imaging

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02476084Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients

N/A

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's D

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01577264Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

N/A

A Study on the Intraject Instructions for Use

N/A

Clinical Trials (1)

NCT00619554A Study on the Intraject Instructions for Use

N/A

Rotigotine patch

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

N/A

Clinical Trials (1)

NCT01095484Named Patient Program With Rotigotine Transdermal System

N/A

Observation of Treatment With Certolizumab Pegol in Daily Practice

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01069419Observation of Treatment With Certolizumab Pegol in Daily Practice

N/A

Verily Study Watch

Parkinson Disease

N/A

Clinical Trials (1)

NCT04985539The Personalized Parkinson Project De Novo Cohort

N/A

Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Rec

N/A

Clinical Trials (1)

NCT00244465Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription

N/A

Social media recruitment

Myasthenia Gravis

N/A

Clinical Trials (1)

NCT06381284Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

N/A

National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthri

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01095393National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)

N/A

lacosamide

Traumatic Brain Injury

N/A

Clinical Trials (1)

NCT01110187A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

N/A

CLassification of Axial SpondyloarthritiS Inception Cohort

Spondyloarthritis

N/A

Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

Brain Tumor Related Epilepsy (BTRE)

N/A

Clinical Trials (1)

NCT02276053Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors

N/A

German Spondyloarthritis Inception Cohort

Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)

N/A

Fecal calprotectin

Crohn's Disease

N/A

Clinical Trials (1)

NCT00496548Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity

N/A

Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Par

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01504529Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine

N/A

UCB Cimzia Pregnancy Follow-up Study

Rheumatoid Arthritis (RA)

N/A

Clinical Trials (1)

NCT02775656UCB Cimzia Pregnancy Follow-up Study

N/A

PatientsLikeMe.com

N/A

Clinical Trials (1)

NCT01762215Policy on Optimal Epilepsy Management

N/A

Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

N/A

Clinical Trials (1)

NCT00302991Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

N/A

Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro

Idiopathic Parkinson's Disease

N/A

Clinical Trials (1)

NCT01159691Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch

N/A

Anti-TNF

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT02804204Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

N/A

Levetiracetam

N/A

Clinical Trials (1)

NCT00319605Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

N/A

Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Soluti

N/A

Clinical Trials (1)

NCT01210690Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution

N/A

Spanish Registry of Systemic Treatments in Psoriasis

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2007

Portfolio: 49 approved products, 146 clinical trials

Top TAs: Neurology, Immunology, Dermatology

Portfolio Health

Pre-Launch11 (22%)

Launch1 (2%)

Growth3 (6%)

Peak4 (8%)

LOE Approaching22 (45%)

Post-LOE8 (16%)

49 total products

Therapeutic Area Focus

21 marketed259 pipeline

5 marketed142 pipeline

17 pipeline

2 marketed5 pipeline

1 marketed5 pipeline

5 pipeline

Gastroenterology

5 pipeline

5 pipeline

Marketed

Pipeline